title: New Age Therapy for Alzheimer's Disease by Neuronal Network Reconstruction.
abstract: Alzheimer's disease (AD) is a recognized incurable neurodegenerative disorder. Clinically prescribed medicines for AD are expected to bring about only slight symptomatic improvement or a delay of its progression. Another strategy, amyloid β (Aβ) lowing agents, has not been successful at memory improvement. We have hypothesized that an improvement in cognitive function requires the construction of neuronal networks, including neurite regeneration and synapse formation; therefore, we have been exploring candidates for radical anti-AD drugs that can restore Aβ-induced neurite atrophy and memory impairment. Our studies found several promising drug candidates that may improve memory dysfunction in AD model mice. The main activity of these drugs is the restoration of damaged axons. Focusing on candidates based on the recovery of neurite atrophy in vitro certainly leads to positive effects on memory improvement also in vivo. This suggests that neuronal network reconstruction may importantly relate to functional recovery in the brain. When identifying the signaling mechanisms of exogenous compounds like natural medicine-derived constituents, molecules directly activated by the compound are hard to be identified. However, the drug affinity responsive target stability (DARTS) analysis may pave the way to an approach to determine the initial molecule of the signaling pathway. Exploring new drug candidates and clarifying their signaling pathways directly relating to neuronal network reconstruction may provide promising therapeutic strategies with which to overcome AD.
authors.affiliation: Division of Neuromedical Science, Department of Bioscience, Institute of Natural Medicine, University of Toyama.
authors.forename: Chihiro
authors.initials: C
authors.lastname: Tohda
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000502:physiology; D000818:Animals; D001284:Atrophy; D004144:Diosgenin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008519:Medicine, Traditional; D009474:Neurons / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D012503:Saponins / Q000494:pharmacology / Q000627:therapeutic use; D054358:Withanolides / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D016229:Amyloid beta-Peptides; D012503:Saponins; D054358:Withanolides; D004144:Diosgenin